First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi

Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients failing induction treatment and who are candidate to autologous stem cell transplantation (ASCT). Brentuximab vedotin (BV) and bendamustine are a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Cancer J
Main Authors: Broccoli, A., Argnani, L., Botto, B., Corradini, P., Pinto, A., Re, A., Vitolo, U., Fanti, S., Stefoni, V., Zinzani, P. L.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906387/
https://ncbi.nlm.nih.gov/pubmed/31827067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0265-x
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker